期刊文献+

多西紫杉醇联合卡培他滨治疗晚期乳腺癌20例 被引量:1

原文传递
导出
摘要 目的观察多西紫杉醇联合卡培他滨(XT)方案治疗晚期乳腺癌的临床疗效及患者不良反应。方法20例晚期乳腺癌患者应用多西紫杉醇75mg/m^2,第1天静脉滴注1h,卡培他滨2000mg/m^2,分早晚两次餐后半小时口服,第1天至第14天。化疗前1天开始口服地塞米松8mg,2次/d,连服3d。3周为1个周期,治疗至少2个周期以上进行疗效评价。结果20例患者CR3例(15%),PR9例(45%),SD6例(40%),PD2例(10%),CR+PR共12例,总有效(RR)率60%。不良反应主要有骨髓抑制、胃肠道反应、手足综合征等,无化疗相关死亡。结论多西紫杉醇联合卡培他滨方案治疗晚期乳腺癌近期临床疗效确切,不良反应可以耐受。
出处 《肿瘤研究与临床》 CAS 2009年第8期480-481,共2页 Cancer Research and Clinic
  • 相关文献

参考文献12

  • 1孙燕 周际昌.内科肿瘤学[M].北京:人民卫生出版社,2003.400.
  • 2江泽飞,宋三泰.紫杉醇在乳腺癌化疗临床应用的新进展[J].中国癌症杂志,2003,13(4):289-292. 被引量:91
  • 3孙燕.临床肿瘤内科手册.4版.北京:人民卫生出版社,2003.571.
  • 4Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences.Oncologist, 2004, 9: 3-8.
  • 5Krasteva-Ruseva R, Zaliariev Z. Combination chemotherapy: docetaxel plus cisp|atin for patients with metastatic breast cancer resistant to previous anthracycline treatment. Ann Oncol, 2005, 16: 279.
  • 6王子平,孙燕,张湘茹,张茂宏,王秀问,于学军,南克俊,李恩孝,刘基巍,高亚杰,关小倩,宋恕平,盛立军,王东林,王志新.多西他赛治疗晚期乳腺癌的临床研究[J].中华肿瘤杂志,2006,28(6):468-470. 被引量:70
  • 7徐兵河.蒽环类耐药性乳腺癌的治疗策略[J].中华肿瘤杂志,2007,29(4):241-244. 被引量:85
  • 8O' Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthraeycline-pretreated 386 capecitabine in metastatic breast cancer patients with advanced breast cancer. Phase Ⅲ trial results. Clin Oncol, 2002, 20: 2812-2823.
  • 9Pronk LC, Vasey P, Sparrboom A, et al. A phase and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumors. Br J Cancer, 2000, 83: 22-29.
  • 10刘跃华,黄静,王雍.卡培他滨联合多西紫杉醇治疗转移性乳腺癌30例[J].肿瘤研究与临床,2008,20(1):59-60. 被引量:2

二级参考文献42

  • 1徐兵河,赵龙妹,袁芃,储大同.多西紫杉醇联合卡培他滨治疗蒽环类药物耐药性晚期乳腺癌的初步临床结果[J].癌症进展,2004,2(1):18-20. 被引量:24
  • 2王涛,江泽飞,宋三泰,张少华,申戈,于静新.单药希罗达治疗复发转移性乳腺癌的疗效观察[J].中华肿瘤杂志,2004,26(6):379-381. 被引量:57
  • 3徐兵河,李维廉,邸立军.诺维本联合顺铂治疗晚期乳腺癌的多中心临床研究[J].中国肿瘤临床,2004,31(23):1340-1342. 被引量:27
  • 4徐兵河,赵龙妹,王佳玉,袁芃.泰索帝联合顺铂治疗31例蒽环类耐药性晚期乳腺癌疗效分析[J].中华肿瘤杂志,2006,28(6):471-473. 被引量:46
  • 5Seidman AD, Tiersten A, Hudis C, et al. Phase Ⅱ trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer [ J ]. J Clin Oncol, 1995,13 ( 10 ) :2575-2581.
  • 6Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HEB2 [ J ]. N Engl J Med,2001,344( 11 ) :783-792.
  • 7Robert N, Leyland-Jones B, Asmar L, et al. Phase Ⅲ comparative study of trastuzumab and paclitaxel with and without carbeplatin in patients with HER-2/neu positive advanced breast cancer[J]. Breast Cancer Res Treat,2002,76(supple) :37.
  • 8Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificanton[ J ]. J Clin Oncol,2001,19 (10) :2587-2595.
  • 9Early Breast Cancer Trialists " Collaborative Group,Polychemotherapy for early breast cancer: an overview of the randomised trials [ J ]. Lancet, 1998,352 (2) :930-934.
  • 10Henderson C, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[ J ]. J Clin Oncol, 2003,21 ( 6 ) :976-983.

共引文献270

同被引文献4

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部